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Abstract: Lentiviruses are known for their narrow cell- and species-tropisms, which are 
determined by cellular proteins whose absence or presence either support viral replication 
(dependency factors, cofactors) or inhibit viral replication (restriction factors). Similar to 
Human immunodeficiency virus type 1 (HIV-1), the cat lentivirus Feline immunodeficiency 
virus (FIV) is sensitive to recently discovered cellular restriction factors from non-host 
species  that  are able to  stop viruses from  replicating. Of particular importance are the 
cellular proteins APOBEC3, TRIM5α  and  tetherin/BST-2. In general, lentiviruses 
counteract or escape their species’ own variant of the restriction factor, but are targeted by 
the orthologous proteins of distantly related species. Most of the knowledge regarding 
lentiviral restriction factors has been obtained in the HIV-1 system; however, much less is 
known about their effects on other lentiviruses. We describe here the molecular 
mechanisms that explain how FIV maintains its replication in feline cells, but is largely 
prevented from cross-species infections by cellular restriction factors. 
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1. Introduction 
In many species of Felidae, including the domestic cat, individuals may be infected with a unique 
strain of feline immunodeficiency virus (FIV), and a related virus is also found in African hyenas (for 
a review, see [1,2]). Viruses isolated from various felid species show monophyletic proviral sequences, 
OPEN ACCESS Viruses 2011, 3      
 
 
1987 
which supports the idea that FIVs are not frequently transmitted between different felid species [2–4]. 
FIV was  introduced into the existing felid lineages at several  different times during evolution.  A  
co-adaptation between FIV and Felidae is assumed to have occurred for at least 10,000 years, and 
possibly as much as a million years for some species [2,3]. In contrast, FIV infection of the domestic 
cat appears to be of more recent origin  [2]. In addition, singular events of  FIV felid-to-felid 
cross-species transmissions and repeated FIV transmissions from bobcats to pumas have been 
observed (for an overview, see [1,5,6]).  
In mammals, including felids, the innate immune system provides a first line of defense against 
pathogens. Induction of type I interferon regulates the expression of several interferon-stimulated 
genes (ISGs) whose protein products have direct antiviral properties. A group of proteins with potent 
antiviral properties, known collectively as “restriction factors,” are constitutively expressed in cells, 
but also induced by type I interferon. These proteins are able to limit replication by targeting specific 
steps in the viral life cycle [7]. However, lentiviruses have developed counteracting proteins to survive 
and replicate in their host mammal. While orthologous cellular proteins, which differ specifically in 
the  interaction sites of  the  counteracting  viral proteins,  limit inter-species transfer,  a  high genetic 
variability in the restriction factors might also limit the spread and extent of infections and disease 
within the natural host population (intra-species transfer) [8].  
FIV infection of felids shows substantial variation in disease outcome: in domestic cats, FIV can 
induce a strong immune pathology with a T cell depletion and immunodeficiency, resulting in 
opportunistic infections as well as weight loss and neurological disease  (for review see [9,10]); 
however, in non-domestic felids infections with FIV appear to be apathogenic in most individuals [1]. 
For example, in FIV-infected lions and pumas,  T cell depletion  without  disease has been 
described [11,12].  Interestingly,  different subtypes of lion FIV may  have different patterns of 
pathogenicity and transmissibility among African lions [13]. Some of these variations  are likely 
influenced by differences in viral adaptation to the restriction factors of their hosts. 
Much of today’s knowledge of  anti-lentiviral restriction factors is  derived from the intensive 
characterization of the interaction of human immunodeficiency virus type 1 (HIV-1) with different 
host cells. However, recent investigations have also focused on how FIV escapes its host species’ own 
restriction factors. Many of the  accessory gene products of HIV-1  counteract  cellular  restriction 
factors. For example, the Vif protein inhibits APOBEC3 cytidine deaminases (see Section 2), while the 
Vpu protein protects HIV-1 from tetherin (see Section 4). Vpr inhibits a cellular factor that is still 
unidentified but, interestingly, Vpx, which is closely related to Vpr (found, for example in Human 
immunodeficiency virus type 2, HIV-2) is a potent inhibitor of SAMHD1 (see Section 5). In contrast to 
HIV-1, FIV has only a vif gene and genes such as vpr, vpx and vpu are not present. Instead, a gene for 
the  less  well-characterized multifunctional protein  OrfA (Orf-A, Orf-2) is uniquely found in  FIV 
(see Section 6). A further restriction factor, TRIM5α, is not counteracted by accessory proteins. While 
all primate lentiviruses evolved in the presence of TRIM5α, the feline lentiviruses did not face this 
protein in their natural hosts because felids express a truncated, inactive variant of the TRIM5 protein 
(see Section 3) [14]. 
The strain-specific evolution of FIVs is likely driven by genetic differences in cellular dependency 
and restriction factors, in addition to selection by the immune system. We can assume that, besides 
differences in these factors, the FIV cross-species transfer from a felid to a felid/non-felid is also Viruses 2011, 3      
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impaired by other limitations. Since FIV infection in domestic cats induces a fatal immunodeficiency 
that is very similar to AIDS in humans [9,10], FIV infection of cats not only provides a unique model 
to investigate the evolutionary role of restriction factors on cross-species transmission, but also virus 
evolution and its impact on AIDS induction. 
2. FIV and APOBEC3 
The mammalian APOBEC3 (A3; apolipoprotein B mRNA editing enzyme catalytic polypeptide 3) 
protein family was discovered through the study of the HIV-1 Vif. HIV-1 virions that are produced in 
permissive cells are able to infect permissive and non-permissive cells, whereas Δvif virons produced 
in non-permissive cells are unable to infect target cells [15,16]. These findings suggested the existence 
of a Vif-sensitive antiviral factor that was later identified as human APOBEC3G (Figure 1a) [17–19]. 
This interferon-inducible cellular factor is  part of the AID/APOBEC gene family,  which share  a 
characteristic zinc (Z)-coordinating catalytic motif (His-X-Glu-X23–28-Pro-Cys-X2–4-Cys) [20]. The A3 
proteins can be classified according to the presence of a Z1, Z2 or Z3 motif (Figure 1b) [21–23]. A 
multiplicity of evolutionary events  driven by host adaptation to viruses—including preservations, 
deletions, duplications,  subfunctionalizations  and  neofunctionalizations—have led to  a  number of 
different forms of A3 genes within mammals [21,23]. Humans express seven A3 proteins (APOBEC3A, 
-B, -C, -D, -F, -G and -H, Figure 1a) with either one or two zinc-coordinating domains that can inhibit 
various retroviruses, endogenous retroelements and DNA viruses [24–28].  
Figure 1. Human and feline APOBEC3 (A3) proteins. (a) Schematic representation of 
human and feline A3  cytidine deaminases. All A3 proteins share at least one zinc   
(Z)-coordinating catalytic motif. The color code indicates the amino acid specificity of the 
different deaminase domains (Z1, Z2  and Z3). Humans express seven A3 proteins,   
A3A–A3H; cats express four A3 proteins, A3Z2a–A3Z2-Z3. (b) Amino acid sequences of 
indicated domains. Group-specific distinctions of Z-domains are highlighted. 
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In the domestic cat, there are three copies of a Z2 gene and a single copy of a Z3 gene (Figure 1a) 
and  are likely present  in other feline species  as well  [23,29,30].  Besides  these  single-Z-domain 
proteins, Felidae express three very similar two-domain A3 proteins (Figure 1a, shown as a single 
A3Z2-Z3 protein for simplicity) by a complex process of read-through transcription and alternative 
splicing [23,29,30]. A feline A3 gene encoding a Z1 domain protein does not exist. In cats, the A3 
genes are polymorphic and are under positive selection, indicating that they are relevant in the “arms 
race” between host and retrovirus [23]. 
The enzymatic activity of virion-encapsidated A3 results in the hydrolytic deamination of cytosine 
bases in the single-stranded viral (−) DNA that is synthesized during reverse transcription, leading to 
viral genome degradation, or to G-to-A hypermutations on the (+) DNA strand (Figure 2) [31–36]. 
However, A3 proteins also have deaminase-independent antiviral activities, and deaminase-deficient 
A3 mutants are still able to reduce accumulation of reverse transcription products [37–41]. The Vif 
protein of HIV-1 forms an interaction between A3 and a ubiquitin E3 ligase complex consisting of 
elongin B and C, cullin5, and ring box-1 [42]; this interaction results in the A3 polyubiquitination that 
leads to proteasome-mediated degradation of the A3 protein [42–46]. In addition, Vif of HIV-1 inhibits 
A3 proteins by other non-degrading mechanisms (for a review, see [24]). Like HIV-1, FIV also 
encodes a Vif protein [23,29,30,47]. FIVs with an inactivated vif gene do not productively infect feline 
blood cells or show replication in cats [48–50]. 
Recent studies show that FIV Vif counteracts the feline A3 antiviral activity [23,29,30,47].  
vif-deficient FIV is moderately inhibited by feline A3Z3 and is strongly suppressed by feline A3Z2-Z3, 
whereas wild-type virus infectivity is not influenced by feline A3 proteins [23,30]. Both FIV and 
FIVΔvif are very sensitive to three of the seven human A3s (A3F, A3G and A3H) [23,30,47]. The 
antiviral activity of feline A3s against FIVΔvif correlated with the detection of cytidine deaminated, 
edited viral genomes [23]. Whether feline A3s also have non-editing antiviral activities has not yet 
been investigated. Further, it is unknown why feline A3Z2 proteins do not inhibit FIVΔvif or FIV. 
However, the feline A3Z2 proteins are active cytidine deaminases and they restrict Bet-deficient 
Feline foamy virus. This feline retrovirus uses its accessory protein, Bet, to counteract the feline A3Z2 
proteins via a degradation-independent pathway [23,51]. In contrast, expression of FIV Vif induces the 
degradation of feline A3s and thus prevents the encapsidation of A3s into FIV particles [29,30,47]. 
The degradation of feline A3 proteins by FIV Vif occurs efficiently in human cells indicating that this 
Vif activity does not depend on species-specific host factors [29,30,47]. It has not yet been shown but 
it is likely that FIV Vif recruits elongin B/C, cullin5, and ring box-1 in human cells as in feline cells to 
induce polyubiquitination of feline A3s. 
Vif proteins can be counteractive, non-active or semi-active against different A3 proteins. 
Surprisingly, the domestic cat FIV Vif protein can efficiently inhibit A3 restriction factors of three 
tested Felidae (puma, lion, lynx) and shows a reduced activity to A3s from the tiger [30]. These results 
indicate that most of the diverse felid A3s of big cats are probably not major determinants that prevent 
cross-species transmission of FIV from the domestic cat to these closely related animal species. In 
contrast, FIV Vif is completely inactive against A3 proteins from primates and other non-felid 
species [23,30,47]. A characterization of the molecular interaction of domestic cat FIV Vif with A3s of 
different felids may reveal the binding domains of Vif and A3; it may also explain the broad activity of 
domestic cat FIV Vif.  Viruses 2011, 3      
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Figure 2. Impact of the cellular restriction factors APOBEC3 (A3), TRIM5α and tetherin 
on FIV replication. The FIV replication cycle starts by infection of either  feline or  
non-feline cells and the resulting  FIV particles then infect a target cell that shows no 
TRIM5α restriction. FIV Vif targets the feline A3 protein for proteasomal degradation but 
it is inactive against A3 proteins from non-felid species . If Vif is not expressed or does 
not bind to A3, A3 is packaged into FIV virions budding from the producer cells  . 
During the next round of infection in target cells, encapsidated A3 proteins act as inhibitors 
of virus replication. Single-stranded viral DNA serves as a substrate for A3-induced 
cytidine deamination, causing hypermutations of the viral DNA, during  which 
deoxycytidines are converted to deoxyuridines. Uracil-containing minus-strand DNA can 
be targeted by uracil DNA glycosylase, which could lead to endonucleolytic cleavage . 
The number of integrated, highly mutated proviruses is low. In non-feline cells, TRIM5α 
restricts FIV soon after post-entry, likely by acceleration of the viral uncoating process. 
TRIM5α  may  also  promote  innate  immune  signaling.  The  truncated  feline  TRIM5α  is 
incapable  of  restricting  retroviruses  . Feline tetherin is not able to restrict direct   
cell-to-cell spread of FIV, but can restrict the release of cell-free particles. A FIV 
antagonist (indicated by a question mark) of feline tetherin has not yet been detected. FIV 
is also inhibited by non-felid tetherin proteins . Many details of this model are based on 
experimental results of HIV-1 in primate cells. 
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3. FIV and TRIM5 
HIV replication in simian cells is blocked during uncoating at the early post-entry stage—a finding 
that was used to identify the restriction factor TRIM5α [52], which is constitutively expressed, but 
interferon treatment can further increase its levels [53]. TRIM5α is a tripartite motif protein with a 
RING, B-box 2 and coiled-coil (CC) domain (RBCC), as well as a carboxy-terminal B30.2 (SPRY) 
domain  (Figure  3a). The B30.2 domain  of  TRIM5α  binds  to  the  viral  capsid  of incoming viral 
particles, while the RBCC  domains mediate the localization to cytoplasmic bodies and are 
important for TRIM5α self-association [54–61]. TRIM5α inhibits HIV-1 and other retroviruses in a 
species-specific manner. Thus retroviruses replicate in the presence of TRIM5α proteins of their host 
species and are inhibited by orthologous TRIM5α proteins. Species-adapted retroviruses evolved viral 
capsids that do not bind TRIM5α proteins expressed in their host species [62]. Simian TRIM5α likely 
acts at several levels: it restricts HIV-1 by accelerating the viral uncoating process, which leads to an 
inhibition of the reverse transcription (Figure 2) [63–65], and TRIM5α also leads to an integration 
block that appears after the reverse transcription block is relieved by inhibition of the proteasome [66]. 
Insights into the multifunctional nature of TRIM5α were obtained in a recent study by Pertel et al. that 
suggests that TRIM5α is a pattern-recognition receptor for HIV-1 (Figure 2) [67]. TRIM5α promotes 
innate immune signaling of the mitogen-activated protein kinase and NF-κB signaling pathways by its 
association  with the retroviral capsid lattice and the E2 ubiquitin-conjugating enzyme complex 
UBC13-UEV1A that activates TAK1 kinase [67]. Furthermore, the authors demonstrated that TRIM5α 
has a specific effect on the expression of NF-κB- and AP-1-responsive inflammatory chemokines and 
cytokines  [67]. The knockdown of TRIM5α  in myeloid cells attenuates lipopolysaccharide  
(LPS)-induced immune signaling and also rescues viral infections from the LPS-induced antiviral gene 
expression [67]. Thus, TRIM5α plays a role in LPS-triggered immune activation through the Toll-like 
receptor 4 pathway. 
Human  and  rhesus  macaque  TRIM5α  can  inhibit  the  infection  of  FIV  if  expressed  in  feline 
cells [54,68]. In single-round infection assays, it appears that the antiviral activity of the rhesus protein 
i s  s t r o n g e r  t h a n  t h a t  o f  h u m a n  T R I M 5 α .  F e l i n e  c e l l s  e x p r e s s i n g  h u m a n  o r  r h e s u s  T R I M 5 α  a l s o  
potently block spreading replication of FIV without the appearance of revertants [68]. Most human cell 
lines, with the exception of HEK 293T, are not permissive for transduction by FIV vectors, especially 
T cell lines that show a strong restriction [68].  
Owl monkeys and macaques express a protein called TRIMCyp due to a cDNA of the cyclophilin A 
(CypA) gene that retrotransposed into the 3′ region of the TRIM5 gene [69–73]. In owl monkeys, the 
CypA cDNA is inserted into intron seven of the TRIM5 gene [71]. A distinct evolutionary origin of 
TRIMCyp is found in three macaque species (M. fascicularis, M. mulatta, and M. nemestrina) where 
the  CypA cDNA retrotransposed in the 3′  untranslated  region  of the TRIM5 gene and macaque 
TRIMCyp is expressed by exon skipping from exon six to CypA [69,70,72,73]. Owl monkey as well 
macaque TRIMCyps consist of the RBCC domains of TRIM5 fused with a carboxy-terminal CypA 
moiety (Figure 3b) [69–74]. CypA binds the surface of the capsid proteins of HIV-1 and FIV that form 
the viral core [75–78]. In FIV, the interaction of CypA can be prevented by a P90A mutation in the 
loop between helix 4 and 5 of the capsid [75,78]. TRIMCyp of Owl monkeys and macaques, or an 
artificial human TRIMCyp, restricts infection with FIV [54,72,73,78–82]. Similar to TRIM5α, treating Viruses 2011, 3      
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rhesus TRIMCyp-expressing feline cells with a proteasome inhibitor relieves the block in the reverse 
transcription of FIV, but does not restore the capacity of FIV to transduce these cells [73]. 
McEwan et al. discovered that Feliformia express a truncated TRIM5 gene, which explains why 
feline cells do not show a TRIM5-typical restriction to retroviruses (Figure 2) [14]. The feline mRNA 
of TRIM5 contains a premature stop codon expressing a RBCC protein without the B30.2 domain 
(Figure 3a). In cats, the missing B30.2 domain is not replaced by CypA as seen in some monkeys [14]. 
The truncated feline TRIM5 appears to be without any antiretroviral activity as overexpression of the 
feline  TRIM5 does not prevent infection with  murine leukemia  virus,  HIV-1  or a simian 
immunodeficiency virus (SIV) of macaques (SIVmac) [14]. However, it is possible that the truncated 
feline TRIM5 protein is similar to  the human  TRIM5α  involved in LPS-mediated signaling  [67], 
potentially explaining why this gene is retained in Feliformia. Interestingly, a synthetic fusion of the 
feline TRIM5 to the feline CypA (Figure 3b) generated a potent inhibitor of FIV and HIV-1 [75,83]. 
These results show that the RBCC domains of feline TRIM5 retain their intrinsic antiviral function.  
Figure 3. Domain structure of TRIM5α and TRIMCyp proteins. (a) TRIM5α is defined by 
four domains: RING finger, B-box 2, coiled-coil and B30.2. The feline TRIM5α lacks the 
B30.2 capsid-binding domain because of a premature stop codon in the mRNA transcript. 
(b) In some monkeys, TRIMCyp is expressed, in which the B30.2 domain of TRIM5α is 
replaced with a cyclophilin A (CypA) domain. Expression of feline TRIMCyp was not 
observed. Dietrich et al. produced a synthetic feline TRIMCyp by fusion of the truncated 
TRIM5α and feline cyclophilin A [75]. 
     
 
4. FIV and Tetherin 
The restriction factor tetherin (also known as CD317 or BST-2 or HM1.24), was identified by 
analyzing  the cell type-specific particle release block of  HIV-1 deficient  for the viral  protein 
Vpu [84,85]. Tetherin is an interferon-induced protein that “tethers” HIV-1Δvpu particles at the cell 
surface (Figure 2). The Vpu protein of HIV-1 interferes with the cell surface expression of human 
tetherin in part by inducing its degradation [86,87]. Primate lentiviruses that lack a vpu gene use either 
their Nef or Env proteins to counteract tetherin in the host cells (for review see [88–90]). In general, Viruses 2011, 3      
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the lentiviral proteins that counteract are only active against tetherin proteins of their own host species. 
In addition to retroviruses, tetherin proteins are also  inhibitory to  herpesviruses, arenaviruses, 
filoviruses, rhabdoviruses, orthomyxoviruses and paramyxoviruses [91–98]. 
Tetherin  is an unusual type II integral membrane protein  (Figure  4)  with an N-terminal 
transmembrane domain, an extracellular CC  domain and a  C-terminal  glycosylphospatidylinositol 
(GPI) lipid anchor at its C-terminus [99]. Recent data indicate that the GPI anchor motif functions as a 
second transmembrane motif [100]. In humans, tetherin is expressed on several specialized cell types 
such as hepatocytes, monocytes, epithelial cells, terminally differentiated B cells and bone marrow 
stromal cells. It is upregulated in many cell types upon treatment with interferon [101]. The feline 
tetherin protein was recently cloned and functionally characterized [83,102]. Similar to human and 
mouse tetherin,  the expression of feline tetherin is  inducible by interferons  but a detailed tissue 
expression pattern has not yet been determined [83,102]. In a transient co-expression system, feline 
tetherin is a potent inhibitor for the  release of FIV and HIV-1  particles  [83]. The release of FIV  
virus-like particles and wild-type particles is also strongly inhibited by the human tetherin [83,91]. 
Apparently, under such experimental conditions, FIV has no viral determinant that inhibits the antiviral 
activity of feline tetherin.  In contrast  to transient expression of tetherin,  stably expressing feline 
tetherin in feline CrFK cells did not restrict virus spread of FIV (human tetherin was not tested) [83]. 
Similarly, in the HIV-1 system, the cell-to-cell transfer of vpu-deficient HIV-1 in T cells was  not 
inhibited by human tetherin [103], although, contrasting results have also been reported [104]. This 
might indicate that Vpu of HIV-1 is not strongly required for viral spread in vivo. Support of this 
model comes from the observation, that in contrast to Vpu of HIV-1 pandemic group M, the Vpus of 
non-pandemic AIDS inducing HIV-1 groups O and N show no, or very low activity, against human 
tetherin [105]. These findings potentially explain why HIV-1 group O and N viruses propagate less 
efficiently in the human population than the pandemic HIV-1 group M virus. Together, these data 
indicate that FIV, in contrast to HIV-1, is transmitted mainly as a cell-associated virus and not as a 
cell-free virus. 
Figure 4. Schematic structure of feline and human tetherin. Tetherins from both species 
share their principal elements: Cytoplasmatic (Cyto)-, transmembrane (TM)-, coiled-coil- 
and glycophosphatidyl-inositol (GPI)-anchor domains. 
     
 
5. FIV and SAMHD1 
Human cells of the myeloid lineage such as blood monocytes or monocyte-derived dendritic cells 
(mDCs), are highly refractory to infection by HIV-1 due to a post-entry restriction [106–111]. Some 
primate lentiviruses, such as SIV endemic to sooty mangabeys (SIVsm), SIVmac and HIV-2, do not 
show this replication restriction  (for a review, see [112]).  Human and feline mDCs also  show  a Viruses 2011, 3      
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resistance against the productive infection with FIV [113–115]. In contrast to HIV-1, lentiviruses such 
as SIVsm/SIVmac/HIV-2 express an accessory protein called Vpx that is specifically encapsidated into 
viral particles [116,117]. Loss of Vpx expression in SIVmac and HIV-2 has no effect on the viral 
replication in established cell lines, but Vpx mutants show a delayed replication in cultures of PBMCs 
(peripheral blood mononuclear cells)  and a replication  block  in  macrophages  [118–120].  In vivo, 
SIVsm (isolate PBj) needs Vpx  expression for efficient dissemination and the acute, unique 
pathogenesis of SIVsmPBj [121]. In infected monkeys, SIVmac Vpx mutants show a lower viremia, a 
delayed CD4 cell decline and a later AIDS induction compared to wild type viruses [122]. Thus, a 
Vpx-function for  AIDS induction by SIVmac is not required and it is unclear why only some 
lentiviruses encode Vpx and infect mDCs.  
In myeloid cells,  Vpx mutants of HIV-2  and  SIVmac  show a post-entry block at reverse 
transcription or uncoating [115,123–125]. The Vpx protein forms a cullin 4-based E3 ubiquitin ligase 
complex (for a review, see [112]) indicating that, similar to Vif, Vpx acts as a substrate receptor to 
induce the degradation of a cellular protein. Recently, the human protein SAMHD1 was identified to 
be causative for the  post-entry restriction of HIV-1 in myeloid cells [126,127].  Viral 
particle-associated Vpx protein induces a proteasome-dependent degradation of SAMHD1 in the target 
cell very early after entry [126,127]. The SAMHD1 protein has two domains that are widely found in 
all genomes: an N-terminal SAM domain followed by a HD domain (Figure 5). SAM (sterile α motif) 
domains have diverse functions, such as binding to kinases, other proteins or RNA [128]. The HD 
domain  with histidine and aspartic acid residues for metal coordination  defines a superfamily of 
metal-dependent phosphohydrolases, which includes many proteins that are involved in nucleic acid 
metabolism such as dGTPases, nucleotidyltransferases and helicases [129]. Mutations in the SAMHD1 
gene lead to Aicardi-Goutieres syndrome, which includes  cerebral atrophy, leukoencephalopathy, 
hepatosplenomegaly, and increased production  of  α-interferon  [130].  The antiviral mechanism of 
SAMHD1 is not yet identified but,  based on the activities of proteins that share homology  with 
SAMHD1, it is likely that SAMHD1 acts either as a nuclease that destroys the viral genetic material of 
incoming viruses, or functions as a sensor (or sensor-associated protein) that induces antiviral proteins. 
It would be interesting to determine whether the feline gene for SAMHD1 (found on cat chromosome 
A3) encodes an antiviral protein, and whether FIV expresses a viral counteracting factor against feline 
SAMHD1 that functions similarly to Vpx. 
Figure 5. Schematic representation of the human SAMHD1 protein indicating the SAM 
and  the  HD domain.  A  putative feline SAMHD1-encoding gene is found on cat 
chromosome 13. 
   
 
 
6. Major Challenges in Research on FIV Restriction Factors 
The HIV-1 origin in humans  is one of best studied lentiviral cross-species transmissions [131]. 
Because of the very high genome sequence identity between the two Hominidae, Pan troglodytes and Viruses 2011, 3      
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Homo sapiens, it is not surprising that SIV of chimpanzees (SIVcpz) quickly adapted and developed a 
pandemic distribution once introduced in the human population. However, the evolution of HIV-2, 
derived from a SIV endemic to sooty mangabeys (SIVsm) demonstrates that lentiviruses can also 
rapidly cross between species in different families, in that case from Cercopithecidae to Hominidae 
[132,133]. FIV cross-species transfers are described so far only in Felidae, and mostly as singular 
events,  with the exception of repeated transmissions of  FIVs  from  bobcats to pumas  [1,5,6].  It is 
unknown what the impact  of restriction factors versus  the relevance of other factors are  in these   
cross-species transmissions [2]. There is a need for more field and laboratory studies that quantitate the 
potential of molecularly  defined feline lentiviruses to establish cross-felid  infections.  It would be 
interesting to learn whether these cross-species transmitted viruses replicate in vivo to similar levels, 
with similar tissue distributions as the species-adapted FIVs, and whether they are rapidly controlled 
by the innate and/or adaptive immune system  of the cat.  Even  for regular FIV infections in the 
domestic cat, information on the importance of cellular restriction factors is limited. Modern methods 
to knock-down the expression of genes or genetically modify FIV target cells with novel restriction 
factors  (to model human HIV-1  gene therapy) will be  useful  in gaining further insights into  the 
evolutionary potential of viral adaptation or its intrinsic constraints, the stability of viral genes and 
genomes, and the impact of restriction factors on the health of infected animals. A recent breakthrough 
is the generation of rhesus TRIMCyp transgenic cats  [82].  PBMCs of theses transgenic animals 
expressed variable amounts of rhesus TRIMCyp and showed a partial resistance to FIV replication [82]. 
Besides the impact of known restriction factors on FIV replication and their use in therapeutic 
models, FIV has not been utilized in a systematic search for antiviral proteins and dependency factors. 
The recent identification of novel restriction factors that are counteracted by accessory proteins of 
HIV-1 raises the question as to whether FIV might also be used to identify novel cellular restriction 
factors.  In this regard,  it might be interesting  to note that FIV encodes  the  protein  OrfA, whose 
function is still enigmatic [134,135]. OrfA does not counteract of feline tetherin [83], but is important 
for replication in vivo and in primary T cells, and its exact role in FIV biology is not yet established. 
Different studies describe  various functions of OrfA  including:  transactivating  viral transcription, 
regulating the infectivity of FIV particles, inducing G2 cell cycle arrest, and downregulating the FIV 
receptor CD134 [136–139].  
The induction of interferon following  FIV infection of  feline PBMCs and  cats  suggests that  
pattern-recognition receptors in hematopoietic cells detect the FIV infection [140]. How FIV or other 
lentiviruses are sensed, whether FIV has evolved partial escape mechanisms of this detection, and 
which feline ISGs show anti-FIV activity need much more investigation. A systematic analysis of all 
ISGs  with FIV and FIV deleted in specific genes could identify factors that are antiviral  and are 
counteracted by FIV’s proteins. In human cells, many interaction partners of A3G, TRIM5α, tetherin 
and  SAMHD1, and of  HIV-1 accessory proteins,  have been described or will be published soon 
(e.g., [42,67,141–143]). Thus, systems biology approaches for FIV and feline cells will be important to 
learn about the conserved and differing pathways used by HIV-1 and FIV. It may also allow us to better 
utilize the FIV cat model to discover novel treatment and healing options for HIV-1-infected patients. 
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